Size isn?t everything
Questions include:
Are the regulatory processes holding back development in fields such as drug delivery?
How important is it that the nanotech industry engages in a dialogue with governments and the public to address these concerns and better explain the value and risks of nanotech?
How would you describe the current financing picture in the life sciences industry?